Nomura Holdings Inc. Has $1.89 Million Stock Position in Hims & Hers Health, Inc. $HIMS

Key Points

• Nomura Holdings Inc. significantly increased its stake in Hims & Hers Health, Inc. by 433.2%, owning 64,055 shares worth approximately $1.89 million after purchasing an additional 52,042 shares.
• Hims & Hers Health reported a net margin of 9.63% and a revenue of $544.83 million in its most recent earnings report, though it missed earnings estimates by $0.01.
• The stock has experienced a 1.7% decline recently, with its current trading price at $41.63, while the twelve-month high was $72.98.

Nomura Holdings Inc. boosted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 433.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 64,055 shares of the company's stock after buying an additional 52,042 shares during the quarter. Nomura Holdings Inc.'s holdings in Hims & Hers Health were worth $1,893,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. UMB Bank n.a. increased its position in Hims & Hers Health by 247.5% during the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after buying an additional 933 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Hims & Hers Health during the first quarter worth about $41,000. Larson Financial Group LLC grew its position in Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock worth $42,000 after buying an additional 458 shares in the last quarter. Tsfg LLC bought a new position in Hims & Hers Health during the first quarter worth about $46,000. Finally, Fifth Third Bancorp lifted its stake in Hims & Hers Health by 165.4% during the first quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock worth $46,000 after purchasing an additional 961 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Hims & Hers Health

In other news, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $45.06, for a total value of $5,773,402.62. Following the completion of the transaction, the chief executive officer owned 89,521 shares of the company's stock, valued at $4,033,816.26. The trade was a 58.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Michael Chi sold 2,100 shares of the business's stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $57.52, for a total transaction of $120,792.00. Following the completion of the transaction, the insider directly owned 278,654 shares of the company's stock, valued at $16,028,178.08. This trade represents a 0.75% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,395,428 shares of company stock worth $71,753,898. 17.71% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of research analyst reports. Morgan Stanley reiterated an "equal weight" rating and issued a $40.00 target price on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Truist Financial cut their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research note on Monday, August 18th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Reduce" and an average price target of $38.92.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock traded up $2.97 during midday trading on Wednesday, reaching $44.50. The company had a trading volume of 30,418,350 shares, compared to its average volume of 27,550,874. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The company has a market capitalization of $10.06 billion, a price-to-earnings ratio of 55.63, a price-to-earnings-growth ratio of 2.86 and a beta of 2.14. The stock has a fifty day simple moving average of $50.02 and a 200 day simple moving average of $45.56. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same period in the prior year, the business earned $0.06 EPS. The business's revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.